Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan;32(1):47-63.
doi: 10.1016/j.soc.2022.07.005. Epub 2022 Nov 3.

Clinical Trials in Melanoma: Margins, Lymph Nodes, Targeted and Immunotherapy

Cimarron E Sharon  1 , Georgia M Beasley  2 , Giorgos C Karakousis  3
Affiliations
Review

Clinical Trials in Melanoma: Margins, Lymph Nodes, Targeted and Immunotherapy

Cimarron E Sharon et al. Surg Oncol Clin N Am. 2023 Jan.

Abstract

Multiple randomized controlled trials have influenced the current standard of care for patients with cutaneous melanoma. Since the development of targeted and immune therapy, studies of adjuvant therapy for patients with resected stage III/IV melanoma have led to the approval of combined B-raf proto-oncogene (BRAF) and mitogen-activated protein kinase kinase inhibitors for patients with a BRAF mutation, and cytotoxic T-lymphocyte associated protein-4 or antiprogrammed cell death-1 therapy for patients without a BRAF mutation. This article discusses the details of the trials that have influenced these treatment decisions, in addition to discussing ongoing trials and possible future directions.

Keywords: Immunotherapy; Melanoma; Sentinel lymph node; Surgical margins; Targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Disclosure Dr Beasley: received clinical trial funding from Istari Oncology, Delcath, Oncosec Medical, Replimune, and Checkmate Pharmaceuticals paid to Duke University. Served one time on the advisory boards for Cardinal Health and Regeneron. Giorgos Karakousis: PI of Investigator Initiated Trial with institutional support by Merck. Advisory board: Merck.

MeSH terms

Substances